Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn
About

News

Buffett's Berkshire forges place in best ideas list

Lex Hall  |  03 Apr 2019Text size  Decrease  Increase  |  
Email to Friend

Investors in Berkshire Hathaway have nothing to fear from the eventual exit of Warren Buffet as the famed holding company has buckets of cash and capital allocation nous, says Morningstar.

Berkshire Hathaway is the latest entrant to Morningstar's Global Best Ideas List along with BioMarin Pharmaceutical and French multinational utility Engie.

BioMarin is trading at a 26 per cent discount to Morningstar's fair value estimate, while Berkshire offers a 16 per cent discount, and Engie a 9 per cent discount.

Morningstar analysts play down the ultimate departure of chairman and chief executive Buffett and vice chairman Charlie Munger, saying it will have less of an impact than investors think.

The increased involvement of Buffett’s two lieutenants Todd Combs and Ted Weschler is an encouraging sign, according to Morningstar, as the pair has “bountiful amounts of capital allocation experience”.

“That said, regardless of who succeeds Buffett and Munger longer term, the next managers at Berkshire will not need to do anything heroic as long as they continue to earn more than the firm's cost of capital, which is extremely low.”

Another positive sign is the fact Berkshire has plenty of cash on hand and a disciplined share repurchase program in place.

Investing Compass
Listen to Morningstar Australia's Investing Compass podcast
Take a deep dive into investing concepts, with practical explanations to help you invest confidently.
Investing Compass

“With our current fair value estimate at $360,000 ($240) per Class A (B) share, Berkshire Hathaway is currently trading at a more-than 15 per cent discount to our fair value estimate, and 1.4 times book value per Class A equivalent share of $212,503 at the end of 2018, which has likely recaptured much of the ground lost during the fourth quarter given the gains in the equity markets since the start of the year,” Morningstar says

Monopoly player: BioMarin Pharmaceutical (BMRN)

The focus of American biotech BioMarin is on rare-disease therapies and its lucrative monopolies in this field equip it with enough competitive advantages to warrant a narrow moat.

By Morningstar's reckoning, the market underestimates the company’s foothold in current markets and its potential to crack new ones, particularly given the strength of its emerging gene therapy pipeline.

BioMarin’s gene therapy pipeline is led by haemophilia therapy ValRox, which has restored normal blood clotting in patients after only one dose.

“We think BioMarin is poised to generate more gene therapy targets and has strong intangible assets due to its innovative products, manufacturing expertise, and global reach among patients with very rare diseases.”

The company reported strong fourth-quarter earnings that were in line with Morningstar’s expectations. Its fair value estimate is unchanged at US$119.

French utility powerhouse: Engie (ENGI)

Engie is a global energy firm formed by the 2008 merger of Gaz de France and Suez and the acquisition of International Power in 2012. It changed its name to Engie from GDF Suez in 2015.

The company operates Europe's largest gas pipeline network, including the French system, and a global fleet of power plants with 71 net gigawatts of capacity and 2.2 net gigawatts under construction.

“It trades at a 22 per cent discount to the sector in terms of 2019 P/E while yielding 5.7 per cent, well above the 5 per cent sector average and unjustified since it has lower leverage than peers and solid fundamentals,” Morningstar says.

“Investments in renewables, increasing achieved power prices, and cost-cutting should drive 2018-23 CAGR of 5 per cent in EPS and about 6.5 per cent in dividend.

“A partial exit of the French gas transmission assets and the sale of the French state’s stake in Engie’s capital would be positive catalysts.”

 

is senior editor for Morningstar Australia

© 2021 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. This information is to be used for personal, non-commercial purposes only. No reproduction is permitted without the prior written consent of Morningstar. Any general advice or 'regulated financial advice' under New Zealand law has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), or its Authorised Representatives, and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. For more information, refer to our Financial Services Guide (AU) and Financial Advice Provider Disclosure Statement (NZ). Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Morningstar’s full research reports are the source of any Morningstar Ratings and are available from Morningstar or your adviser. Past performance does not necessarily indicate a financial product's future performance. To obtain advice tailored to your situation, contact a licensed financial adviser. Some material is copyright and published under licence from ASX Operations Pty Ltd ACN 004 523 782. The article is current as at date of publication.

Email To Friend